(Q37971873)

26 August 2017

title

Targeting the endothelin axis in prostate carcinoma (English)

1 reference

26 August 2017

Alvaro Pinto

1

1 reference

26 August 2017

María Merino

2

1 reference

26 August 2017

Pilar Zamora

3

1 reference

26 August 2017

Andrés Redondo

4

1 reference

26 August 2017

Beatriz Castelo

5

1 reference

26 August 2017

Enrique Espinosa

6

1 reference

26 August 2017

publication date

29 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

33

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

421-426

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-011-0299-6

26 August 2017

exact match

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Targeting bone metastasis in prostate cancer with endothelin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Endothelin receptors as novel targets in tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Growth regulatory properties of endothelins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

The endothelin axis: emerging role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Endothelins and hypoxia-inducible factor in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Emerging role of the endothelin axis in ovarian tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

The endothelin axis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Epithelial-mesenchymal transition in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Identifying novel prostate cancer associated pathways based on integrative microarray data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappaB binding and histone acetylation at specific kappaB sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Estrogens affect endothelin-1 mRNA expression in LNCaP human prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0299-6

Protein kinase C delta but not PKC epsilon activity is involved in contractile potentiation by endothelin-1 in the porcine coronary artery

21 January 2018

1 reference

12 December 2020

Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma

1 reference

12 December 2020

Expression of endothelin receptor a associated with prostate cancer progression

1 reference

12 December 2020

ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain

1 reference

12 December 2020

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer

1 reference

12 December 2020

Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception

1 reference

12 December 2020

Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer

1 reference

12 December 2020

Endothelin-1 and metastatic cancer pain

1 reference

12 December 2020

Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer

1 reference

12 December 2020

10.1007/S13277-011-0299-6

Identifiers

DOI

1 reference

26 August 2017

1 reference